Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation

Not Applicable

Completed

• Conditions: Obesity; Muscle Mass; Ectopic Fat; Body Composition; Overfeeding
• Interventions: Dietary Supplement: PUFA-group; Dietary Supplement: SFA-group

• Registration Number: NCT02211612
• Lead Sponsor: Uppsala University

Brief Summary

To investigate metabolic and molecular response to fatty acid-specific overfeeding in overweight subjects, in relation to changes in ectopic fat, lean tissue mass and insulin sensitivity

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-08-06
• Study First Submitted QC: 2014-08-06
• Study First Posted: 2014-08-07
• Study Start: 2014-09
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-25
• Last Update Posted: 2016-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Body mass index 25-32

Exclusion Criteria

• Type 2 diabetes
• Type 1 diabetes
• Kidney disease
• Liver disease
• Abnormal clinical chemistry at screening
• Intense physical exercise > 2 hours per week
• Use of statins or drugs affecting energy metabolism
• Use of extreme diets

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Polyunsaturated fatty acids (PUFA)-group	PUFA-group	Weight gain created by addition of muffins baked on polyunsaturated fat
Saturated fatty acids (SFA)-group	SFA-group	Weight gain created by addition of muffins baked on saturated fat

Primary Outcome Measures

Name	Time	Method
Change in lean tissue mass	10 weeks	Assessed by magnetic resonance imaging (MRI) and air displacement plethysmography (BodPod)

Secondary Outcome Measures

Name	Time	Method
Change in hepatic fat content	10 weeks	Assessed by magnetic resonance imaging (MRI)
Change in visceral adipose tissue (VAT)	10 weeks	Assessed by magnetic resonance imaging (MRI)
Change in total adipose tissue	10 weeks	Assessed by magnetic resonance imaging (MRI)
Change in pancreatic fat	10 weeks	Assessed by MRI
Change in insulin sensitivity	10 weeks	Assessed by oral glucose tolerance test (OGTT)
Change in plasma lipids	10 weeks	Plasma cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, apolipoprotein B, apolipoprotein A1, free fatty acids, glycerol, proprotein convertase subtilisin/kexin type 9
Change in circulating inflammation and coagulation markers	10 weeks	Plasma tumor necrosis factor-receptor 2, Interleukin receptor 1 antagonist, C-reactive protein, fibrinogen, adhesion molecules

Trial Locations

Locations (1)

Uppsala University; Clinical nutrition and metabolism; Dept of public health and caring sciences; 🇸🇪 Uppsala, Please Select, Sweden